While TTN mutation count has been proposed as a surrogate marker for tumor mutational burden (TMB) in hypermutated tumors such as melanoma and colorectal cancer, its correlation with TMB is markedly weaker in cancers with lower mutation rates, including breast, kidney, and thyroid cancers [28]. This evidence concerns the gene TTN and cancer.